ReviewMolecular biology reports2026
Diagnostic and therapeutic significance of selected antibodies against advanced glycation end-products (anti-AGEs).
Review in Molecular biology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The aim of this review is to summarize current knowledge on the diagnostic and therapeutic significance of antibodies against advanced glycation end-products (anti-AGEs). AGEs are formed through non-enzymatic reactions of reducing sugars with proteins, lipids, and nucleic acids, and their accumulation has been implicated in the pathogenesis of chronic diseases such as diabetes, atherosclerosis, cancer, and neurodegenerative disorders. This paper discusses anti-MGO modified proteins, anti-imidazolone, anti-pentosidine, anti-CML (including SIWA318H), anti-CEL, anti-CMA, and anti-GA-pyridine antibodies, with a focus on their potential applications in diagnostics (biomarkers, disease progression monitoring) and therapy (e.g., SIWA318H in pancreatic cancer). The review also highlights current limitations, particularly regarding clinical use in humans, and outlines perspectives for further research in this promising field.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.